

Mitochondrial Replacement Techniques: Ethical, Social, and Policy Considerations

Public Discussion Meeting

Monday, March 21, 2016

**National Academy of Sciences Building
Lecture Room
2101 Constitution Avenue, N.W.
Washington, DC**

Background and Meeting Objectives:

- On February 3, 2016 the IOM publicly released the report, *Mitochondrial Replacement Techniques: Ethical, Social, and Policy Considerations*, in which it is concluded that it is ethically permissible to conduct clinical investigations of mitochondrial replacement techniques (MRT), subject to certain conditions and principles laid out in the report.
- The objectives of this meeting are:
 - Discuss the report's findings, conclusions, and recommendations.
 - Hear a range of perspectives and reactions to the report and provide a venue for open dialogue.

1:30 p.m. **FDA Perspective**

Celia Witten, Director, Office of Cellular, Tissue, and Gene Therapy,
CBER/FDA

1:45 p.m. **Overview of Committee's Report**

Jeffrey Kahn, Committee Chair, Johns Hopkins University
Marni Falk, Committee Member, University of Pennsylvania and The
Children's Hospital of Philadelphia
James Childress, Committee Member, University of Virginia
R. Alta Charo, Committee Member, University of Wisconsin - Madison

2:10 p.m. **Q&A/Discussion**

3:00 p.m. **Adjourn**